0000950170-23-030533.txt : 20230629 0000950170-23-030533.hdr.sgml : 20230629 20230629070137 ACCESSION NUMBER: 0000950170-23-030533 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230627 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230629 DATE AS OF CHANGE: 20230629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Marpai, Inc. CENTRAL INDEX KEY: 0001844392 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40904 FILM NUMBER: 231054268 BUSINESS ADDRESS: STREET 1: 5701 EAST HILLSBOROUGH AVENUE, SUITE 141 CITY: TAMPA STATE: FL ZIP: 33610 BUSINESS PHONE: 646-303-3483 MAIL ADDRESS: STREET 1: 5701 EAST HILLSBOROUGH AVENUE, SUITE 141 CITY: TAMPA STATE: FL ZIP: 33610 8-K 1 mrai-20230627.htm 8-K 8-K
0001844392--12-31false00018443922023-06-272023-06-27

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2023

 

 

MARPAI, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40904

86-1916231

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

5701 East Hillsborough Avenue, Suite 1417

 

Tampa, Florida

 

33610

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 646 303-3483

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Class A Common Stock, par value $0.0001 per share

 

MRAI

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Effective as of June 29, 2023, Marpai, Inc. (the “Company”) effected a reverse stock split of its outstanding shares of Class A common stock (the “common stock”) at a ratio of one-for-four (the “Reverse Split”). The Reverse Split, which was approved by the Company’s board of directors and a majority of its stockholders at the Company’s special meeting convened on June 26, 2023, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on June 27, 2023 (the “Certificate of Amendment”).

 

Effects of the Reverse Split

Effective Date; Symbol; CUSIP Number. The Reverse Split took effect at 12:01 a.m. Eastern Standard Time on June 29, 2023, and was reflected with the Nasdaq Capital Market (“Nasdaq”) and in the marketplace at the open of business on June 29, 2023 (the “Effective Date”), whereupon the shares of common stock began trading on a split-adjusted basis. In connection with the Reverse Split, the Company’s common stock will continue to trade on Nasdaq under the symbol “MRAI” but will trade under a new CUSIP Number, 571354208.

Split Adjustment; No Fractional Shares. On the Effective Date, the total number of shares of the Company’s common stock held by each shareholder were converted automatically into the number of whole shares of common stock equal to (i) the number of issued and outstanding shares of common stock held by such shareholder immediately prior to the Reverse Split, divided by (ii) four.

No fractional shares will be issued, and no cash or other consideration will be paid. Instead, the Company will issue one additional whole share of the post-Reverse Split common stock to any shareholder who otherwise would have received a fractional share as a result of the Reverse Split.

State Filing. The Reverse Split was effected by the Company filing the Certificate of Amendment with the Secretary of State of the State of Delaware on June 27, 2023. The Certificate was not effective until the Effective Date. A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

Capitalization. Prior to the Effective Date of the Certificate, the Company was authorized to issue227,791,050 shares of common stock and the Reverse Split has no impact on such amount. As of June 28, 2023 (immediately prior to the Effective Date), there were 29,012,464 shares of common stock outstanding. As a result of the Reverse Split, there will be approximately 7,253,116 shares of common stock outstanding (subject to adjustment due to the effect of rounding fractional shares into whole shares). The Reverse Split will not have any effect on the stated par value of the common stock.

Each shareholder’s percentage ownership interest in the Company and proportional voting power remains virtually unchanged as a result of the Reverse Split, except for minor changes and adjustments that will result from rounding fractional shares into whole shares. The rights and privileges of the holders of shares of common stock will be substantially unaffected by the Reverse Split.

All options, convertible securities, unvested shares of restricted stock and warrants of the Company outstanding immediately prior to the Reverse Split will be appropriately adjusted by dividing the number of shares of common stock into which the options, convertible securities, unvested shares of restricted stock, restricted stock units and warrants are exercisable or convertible by four and multiplying the exercise or conversion price thereof by four, as a result of the Reverse Split.

Item 8.01 Other Events.

On June 28, 2023, the Company issued a press release announcing the Reverse Split. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.

Description

3.1

Certificate of Amendment to Certificate of Incorporation of the Company

99.1

Press release of Marpai, Inc., dated June 28, 2023

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

MARPAI, INC.

 

 

 

 

Date:

June 29, 2023

By:

/s/ Edmundo Gonzalez

 

 

 

Name: Edmundo Gonzalez
Title: Chief Executive Officer

 


EX-3.1 2 mrai-ex3_1.htm EX-3.1 EX-3.1

 

img236821829_0.jpg 

CERTIFICATE OF AMENDMENT OF

CERTIFICATE OF INCORPORATION OF

MARPAI, INC.

Marpai, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that:

FIRST: The name of the Corporation is Marpai, Inc.

SECOND: This certificate of amendment (this “Certificate of Amendment”) amends the provisions of the Corporation’s certificate of incorporation, as amended (the “Certificate of Incorporation”), last amended and filed with the Secretary of State of the State of Delaware on September 2, 2021.

THIRD: Article IV of the Certificate of Incorporation is hereby amending Section 3 to effectuate the Reverse Split (as defined below) as follow:

“Upon the filing of this Certificate of Amendment with the Secretary of State of the State of Delaware (the “Effective Time”), each four (4) outstanding shares of Common Stock outstanding immediately prior to the Effective Time (the “Old Common Stock”) shall be combined and converted into one (1) share of Common Stock (the “New Common Stock”) based on a ratio of one share of New Common Stock for each four shares of Old Common Stock (the “Reverse Split Ratio”). This reverse stock split (the “Reverse Split”) of the outstanding shares of Common Stock shall not affect the total number of shares of capital stock, including the Common Stock, that the Company is authorized to issue, which shall remain as set forth under this Article IV.

The Reverse Split shall occur without any further action on the part of the Company or the holders of shares of New Common Stock and whether or not certificates representing such holders’ shares prior to the Reverse Split are surrendered for cancellation. No fractional interest in a share of New Common Stock shall be deliverable upon the Reverse Split, all of which shares of New Common Stock be rounded up to the nearest whole number of such shares. All references to “Common Stock” in this Certificate of Incorporation shall be to the New Common Stock.

The Reverse Split will be effectuated on a stockholder-by-stockholder (as opposed to certificate-by-certificate) basis, except that the Reverse Split will be effectuated on a certificate-by-certificate basis for shares held by registered holders. For shares held in certificated form, certificates dated as of a date prior to the Effective Time representing outstanding shares of Old Common Stock shall, after the Effective Time, represent a number of shares of New Common Stock as is reflected on the face of such certificates for the Old Common Stock, divided by the Reverse Split Ratio and rounded up to the nearest whole number. The Company shall not be obligated to issue new certificates evidencing the shares of New Common Stock outstanding as a result of the Reverse Split unless and until the certificates evidencing the shares held by a holder prior to the Reverse Split are either delivered to the Company or its transfer agent, or the holder notifies the Company or its transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with such certificates.”

FOURTH: This Certificate of Amendment was duly adopted in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware.

FIFTH: This Certificate of Amendment shall be effective as of 12:01 a.m. New York Time on June 29, 2023.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its officer thereunto duly authorized this 27th day of June, 2023.

 

MARPAI, INC.

By:

 /s/ Edmundo Gonzalez

 

Name: Edmundo Gonzalez

 


 

 

Title: Chief Executive Officer

 

 

IF " DOCVARIABLE "SWDocIDLocation" 1" = "1" " DOCPROPERTY "SWDocID" 4873-8048-1642, v.4" "" 4873-8048-1642, v.4


EX-99.1 3 mrai-ex99_1.htm EX-99.1 EX-99.1

 

img155121336_0.jpg 

Marpai Announces Reverse Stock Split

NEW YORK--(BUSINESS WIRE)—June 28, 2023 - Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an artificial intelligence (AI) enabled Third-Party Administrator (TPA) transforming self-funded employer health plans, announces a reverse stock split of its Class A common stock (“Reverse Split”) of one post-split share for every four pre-split shares. The Company expects that the common stock will begin trading on a split-adjusted basis at the open of trading on Thursday, June 29, 2023, under the new CUSIP number 571354208. The Reverse Split is an effort to regain compliance with Nasdaq’s listing rules.

 

The Company obtained shareholder approval for the Reverse Split at a special meeting of shareholders on June 26, 2023. The Company’s board of directors then approved the Reverse Split ratio of 4 to 1. The principal purpose of the Reverse Split is to decrease the total number of shares of common stock outstanding and proportionately increase the market price of the common stock in order to meet the continued listing requirements of The Nasdaq Capital Market. The Company's common stock will continue to trade under the symbol "MRAI."

 

As a result of the Reverse Split, every four shares of the Company's common stock issued and outstanding will be automatically reclassified into one new share of common stock. The Reverse Split will not modify any rights or preferences of the shares of the Company's common stock. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, convertible notes, and warrants, as applicable. The common stock issued pursuant to the Reverse Split will remain fully paid and non-assessable. The Reverse Split will not affect the number of authorized shares of common stock or the par value of the common stock.

 

American Stock Transfer & Trust Company, LLC has been appointed by the Company to act as its exchange agent for the Reverse Split. Stockholders owning pre-split shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the Reverse Split and will not be required to take further action in connection with the Reverse Split, subject to brokers’ particular processes. Similarly, registered stockholders holding pre-split shares of the Company's common stock electronically in book-entry form are also not required to take further action in connection with the Reverse Split. Holders of certificated shares will be contacted by the Company or its exchange agent with further details about how to surrender old certificates.

 

For more information, please visit https://ir.marpaihealth.com for more information.

About Marpai, Inc.

 

Marpai, Inc. (Nasdaq: MRAI) is an AI-powered Third Party Administrator (TPA) delivering health plan administration and services to employers that directly pay for employee health benefits (self-funded employer health plans). As a technology innovator in the $22 billion TPA sector representing over $1 trillion in annual claims, Marpai includes services beyond traditional TPA services that improve health plan value to members, and significantly reduce medical and pharmaceutical costs for members and the plan. By leveraging AI and big data, Marpai proactively enables early clinical interventions by proven value-based care providers that can mitigate and reverse costly conditions and avoid costly care. Marpai also helps members fill gaps in annual care and guides them to high-value in-network providers and affordable pharmacy solutions. Operating nationwide, Marpai offers access to provider networks including Aetna and Cigna and delivers all standard TPA services. For more information, visit www.marpaihealth.com or https://ir.marpaihealth.com for investors.

 

 

IF " DOCVARIABLE "SWDocIDLocation" 1" = "1" " DOCPROPERTY "SWDocID" 4889-7630-2956, v.3" "" 4889-7630-2956, v.3


 

Forward-Looking Statement Disclaimer


This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding revenues, employee lives and cash. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings, market changes, and risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise. More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission (the “SEC”). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

Investor Relations Contact:
Simon Li
simonli@marpaihealth.com
(813) 822-3950

 

 

 

IF " DOCVARIABLE "SWDocIDLocation" 1" = "1" " DOCPROPERTY "SWDocID" 4889-7630-2956, v.3" "" 4889-7630-2956, v.3


GRAPHIC 4 img155121336_0.jpg GRAPHIC begin 644 img155121336_0.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH ***IZGJ4.E6J7$ZR,CW$%N @!.Z658E/)'&YP3[9Z M]* +E%%% !1110 4444 %%%% !1110 4444 %%%% ')_$F/S? MW'Y,4V^XM M5\J4X1\W$?RMP>#T/!^AJ/2/#+VLUPT7AKP]X?F>!DBO])999D8XQPUN@QWY M)Z#CTZ35=*L]:TZ2POXVDMI"I94D:,Y5@RD,I!!! /![5G+X0TM4E0S:O(DL M;1.LNLW<@*L,'AI3@^_44 >=R^(M8\5>"?$%Q<7=NBZ>(K$0Q*&2YF$B$W.< M;O+;C8 <$;NO&-?6]2U339-9T>ZU%M26!=,N8I;NVA)4RW6QUVJ@4CY 02,@ MD\],=A/X2T*X #6"JHM4L]D4CQJ848,B%5(!"D<=QD@<$YEO?#FDZA=7%S=6 MGF37"0QRMYCC,,2>.O?(H X:VFU;1[76=^,M'G-[) L>I:RGE00PHC!)R.?DR2PP& M.C2WVNZ=>7.AG7]+AA MD1M/W1$),2NV79*RH_RAEY.5W< Y..8T>PO-9TK1M1U/0W\0:="MY;K8&6*3 MRF6X=8Y,3,JR?NU"AB=PZ@'<37H>K>'M-UIXI+R.82Q*R)+;W,EO(%;&Y=\; M*Q4X&5)QP..*AN_"6B7D%M"UH\"6L)@A^QW$EL5B.,QYB924X'RDXX'% %+P M#=7-[X'L9;AV,N9HU9G,A"K*ZI\QY;Y0OS'D]>]XN2NYB;F(]% 50,X ]\D^D6^G6MI]G%M&88[>'R(H8G98E3CCRP=O&T M8.,@9 P"1110 4444 %%%% !1110 4444 %%%% !1110!__9 end GRAPHIC 5 img236821829_0.jpg GRAPHIC begin 644 img236821829_0.jpg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end EX-101.LAB 6 mrai-20230627_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Current Fiscal Year End Date Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 7 mrai-20230627_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 8 mrai-20230627.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Jun. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Current Fiscal Year End Date --12-31
Document Period End Date Jun. 27, 2023
Entity Registrant Name MARPAI, INC.
Entity Central Index Key 0001844392
Entity Emerging Growth Company true
Securities Act File Number 001-40904
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 86-1916231
Entity Address, Address Line One 5701 East Hillsborough Avenue, Suite 1417
Entity Address, City or Town Tampa
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33610
City Area Code 646
Local Phone Number 303-3483
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol MRAI
Security Exchange Name NASDAQ
XML 10 mrai-20230627_htm.xml IDEA: XBRL DOCUMENT 0001844392 2023-06-27 2023-06-27 0001844392 --12-31 false 8-K 2023-06-27 MARPAI, INC. DE 001-40904 86-1916231 5701 East Hillsborough Avenue, Suite 1417 Tampa FL 33610 646 303-3483 false false false false Class A Common Stock, par value $0.0001 per share MRAI NASDAQ true true EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports mrai-20230627.htm mrai-20230627.xsd mrai-20230627_lab.xml mrai-20230627_pre.xml mrai-ex3_1.htm mrai-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mrai-20230627.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "mrai-20230627.htm" ] }, "labelLink": { "local": [ "mrai-20230627_lab.xml" ] }, "presentationLink": { "local": [ "mrai-20230627_pre.xml" ] }, "schema": { "local": [ "mrai-20230627.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mrai", "nsuri": "http://www.marpaihealth.com/20230627", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "mrai-20230627.htm", "contextRef": "C_eea31774-3b66-4b6a-979a-f294cf01ea89", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "mrai-20230627.htm", "contextRef": "C_eea31774-3b66-4b6a-979a-f294cf01ea89", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.marpaihealth.com/20230627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0000950170-23-030533-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-030533-xbrl.zip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